Lightlake Therapeutics Inc. Appoints New Board Member

Marketwired

LONDON--(Marketwire -04/17/12)- Lightlake Therapeutics Inc. (OTC.BB: LLTP.OB - News) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it has appointed Kevin A. Pollack to the Company's Board of Directors.

Mr. Pollack is a Managing Director at Paragon Capital, an investment firm based in New York City, and also the President of Short Hills Capital LLC, a FINRA broker-dealer based in New York City. He previously specialized in corporate finance and mergers and acquisitions at Banc of America Securities, and he also practiced corporate, securities and mergers and acquisitions law at Sidley Austin (formerly Brown & Wood), a global law firm. Mr. Pollack graduated magna cum laude from The Wharton School of the University of Pennsylvania and holds J.D. and M.B.A. degrees from Vanderbilt University, where he graduated with Beta Gamma Sigma honors.

"I am absolutely delighted to join Lightlake's Board," said Mr. Pollack. "The Company's highly experienced management team, cutting edge research in addiction treatment and strong patent portfolio position Lightlake extremely well for future growth, and I look forward to utilizing my biopharmaceutical, business, finance, legal and public markets expertise to enhance the value of the Company."

About Lightlake Therapeutics Inc.

Lightlake Therapeutics Inc. is a developing biopharmaceutical company aiming to build a platform of biopharmaceutical solutions to common addictions and related disorders. Currently, the Company is focused on providing a safe, effective and simple treatment for patients who are obese or overweight as a result of Binge Eating Disorder in addition to those patients suffering from Bulimia Nervosa. Lightlake recently acquired patents that will allow it to widen its product pipeline to address patients with addictions to opioid painkillers, methadone, cocaine and amphetamine. The Company anticipates launching a development program for each of these purposes in the future.

Safe Harbor

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact:
Investor
Mr. Kevin Fickle
President
NUWA Group LLC
Tel: +1-925-330-8315
Email: kevin@nuwagroup.com
Company
Dr. Roger Crystal
Lightlake Therapeutics Inc.
Tel: +44(0)-207-034-1943
Email: roger.crystal@lightlaketherapeutics.com

View Comments